Pfizer
PFE
$25.01
+0.40%
Pfizer Inc. is a global pharmaceutical giant engaged in the discovery, development, and manufacture of prescription drugs and vaccines, with a portfolio spanning oncology, immunology, cardiology, and infectious diseases. As one of the world's largest drugmakers by revenue, Pfizer holds a dominant position in vaccines (e.g., Prevnar) and cardiovascular therapies (e.g., Eliquis, Vyndaqel), competing fiercely with peers like Merck and AbbVie. The current investor narrative centers on Pfizer's transition post-COVID, as it grapples with patent expirations on key products, a high 6.9% dividend yield that signals income appeal but also market skepticism, and a recent clinical trial failure in GLP-1 that has dampened growth expectations. Leadership changes, including a CFO transition, add to near-term uncertainty, while the company's pipeline and cost-cutting measures are under scrutiny as it aims to restore revenue growth and investor confidence.…
PFE
Pfizer
$25.01
Related headlines
Investment Opinion: Should I buy PFE Today?
Pfizer is rated a Buy, supported by the analyst consensus and a 15% upside to the average target of $28.75. The thesis is that the stock is undervalued on forward earnings, with a P/E of 8.8x versus the industry's 15x, and that the market is overly pessimistic about the patent cliff. The 5.4% revenue growth in Q1 2026 and a strong gross margin of 70.3% provide evidence that the core business is stabilizing, while the 6.9% dividend yield offers a compelling income component.
Sign up to view all
PFE 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between a deeply discounted valuation and significant operational challenges. The forward P/E of 8.8x is attractive, but the market is pricing in a recovery that may not materialize if patent cliffs and pipeline failures persist. The high dividend yield offers a margin of safety, but the negative relative strength indicates that the stock is out of favor. Upgrades to a bullish stance would require evidence of accelerating revenue growth and successful pipeline execution, while downgrades would be triggered by further clinical setbacks or a dividend cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $28.75 and implied upside of +14.9% versus the current price.
Average Target
$28.75
0 analysts
Implied Upside
+14.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$24 - $35
Analyst target range
Pfizer is covered by 26 analysts, with a consensus recommendation of 'buy' and a mean rating of 2.46 (where 1 is strong buy and 5 is sell). The average target price is $28.75, implying a 15% upside from the current price of $25.01, while the low target of $24.00 suggests limited downside risk. The consensus leans bullish, but recent actions show a mixed tone: BMO and Guggenheim reaffirmed positive ratings in July, while HSBC downgraded from Buy to Hold, and RBC upgraded from Underperform to Sector Perform, indicating a cautious optimism. The target range of $24.00 to $35.46 is wide, reflecting high uncertainty about Pfizer's pipeline and patent cliff; the high target assumes successful execution of new drug launches and margin expansion, while the low target prices in continued revenue erosion and clinical setbacks. Overall, the analyst community sees value at current levels, but the wide spread signals that conviction is not uniform.
Bulls vs Bears: PFE Investment Factors
Pfizer presents a classic value-versus-value-trap dilemma. The bull case rests on a deeply discounted forward P/E of 8.8x, a resumption of revenue growth at 5.4% YoY, and a high 6.9% dividend yield that provides income support. The bear case highlights patent expirations, a failed GLP-1 trial, and negative relative strength, which suggest the market is pricing in continued challenges. Currently, the bearish evidence is slightly stronger due to the tangible threats from patent cliffs and competitive pressures, but the valuation is so low that the risk/reward is skewed favorably for patient investors. The most critical tension is whether Pfizer can successfully execute its pipeline and cost-cutting plans to offset the patent cliff; if it does, the stock could re-rate significantly higher, but if it fails, the dividend and earnings could come under further pressure.
Bullish
- Forward PE of 8.8x is deeply discounted: Pfizer trades at a forward P/E of 8.8x versus the industry average of 15x, a 41% discount. This implies the market is pricing in significant earnings growth or a recovery that is not yet reflected in the stock price, offering substantial upside if the company meets its 2026 EPS estimate of $2.35.
- Revenue growth resumed at 5.4% YoY: Q1 2026 revenue of $14.45 billion grew 5.4% year-over-year, marking a return to growth after several quarters of decline. This stabilization is driven by the Biopharma segment, which contributed $14.16 billion, indicating core operations are recovering from the COVID product cliff.
- High dividend yield of 6.9% provides income support: Pfizer's dividend yield of 6.9% is historically high and well above the S&P 500 average, offering a compelling income stream. With a payout ratio of 125.8%, the dividend is currently not fully covered by earnings, but the company's free cash flow of $9.48 billion TTM provides a cushion, and management has signaled commitment to maintaining it.
- Analyst consensus is Buy with 15% upside: The average analyst target price is $28.75, implying a 15% upside from the current price of $25.01. With 26 analysts covering the stock and a mean rating of 2.46 (between Buy and Hold), the consensus is cautiously optimistic, and the low target of $24.00 suggests limited downside.
Bearish
- Patent expirations threaten revenue base: Key drugs like Eliquis and Prevnar face patent cliffs in the coming years, with Merck's Capvaxive already expanding its label to compete in the pneumococcal vaccine market. This competitive pressure could erode Pfizer's market share and revenue, as seen in the recent FDA label expansion for Merck's vaccine.
- Failed GLP-1 trial dents growth prospects: Pfizer's clinical trial failure in the GLP-1 obesity drug class has dampened expectations for a major growth driver. This setback is particularly significant given the booming market for weight-loss drugs, where competitors like Eli Lilly and Novo Nordisk are thriving, leaving Pfizer without a key growth catalyst.
- Earnings volatility and one-time charges: Net income swung to a loss of -$1.65 billion in Q4 2025 due to one-time charges, and the trailing P/E of 18.3x is at a 22% premium to the industry average. This volatility, driven by impairments and restructuring costs, makes earnings quality less predictable and could lead to further negative surprises.
- Negative relative strength versus market: Pfizer's stock has underperformed the S&P 500 significantly over the past year, with a relative strength of -10.8% over 1 year and -13.4% over 6 months. This persistent underperformance reflects investor skepticism and a lack of momentum, which could continue if the company fails to deliver on its turnaround.
PFE Technical Analysis
Pfizer's stock is in a clear downtrend over the past year, with a 1-year price change of +7.4% masking significant volatility; the current price of $25.01 sits near the lower end of its 52-week range, at roughly 87% of the range (from low of $23.11 to high of $28.75). This positioning near the lows suggests a value opportunity for some, but also reflects persistent selling pressure and a lack of bullish conviction, as the stock has failed to sustain rallies above $28. The 6-month change of -5.4% and 3-month change of -5.0% confirm the intermediate-term downtrend, with the stock making lower lows since April 2026.
Beta
0.31
0.31x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$23-$29
Price range past year
Annual Return
+7.4%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | +0.3% |
| 3m | -5.0% | +4.0% |
| 6m | -5.4% | +8.3% |
| 1y | +7.4% | +20.2% |
| ytd | -0.7% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory shows a modest recovery, with Q1 2026 revenue of $14.45 billion, up 5.4% year-over-year, following a mixed 2025 where Q4 revenue surged to $17.56 billion but Q2 dipped to $14.65 billion. The growth is driven by the Biopharma segment, which contributed $14.16 billion in Q1, while the corporate nonsegment added $289 million, indicating core operations are stabilizing after the COVID product decline. However, the multi-quarter trend is uneven, with revenue growth fluctuating from -17% in Q2 2024 to +5.4% in Q1 2026, suggesting the company is still navigating patent expirations and pipeline launches. Net income swung to a loss of -$1.65 billion in Q4 2025 due to one-time charges, but Q1 2026 returned to profitability with $2.69 billion, reflecting an improved net margin of 18.6%.
Quarterly Revenue
$14.5B
2026-03
Revenue YoY Growth
+5.4%
YoY Comparison
Gross Margin
67.3%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given Pfizer's positive trailing net income (EPS of $0.47 in Q1 2026 and positive TTM earnings), the PE ratio is the primary valuation metric. The trailing PE stands at 18.3x, while the forward PE is 8.8x, a significant gap that implies the market expects earnings to more than double in the coming year, driven by cost cuts and pipeline contributions. This forward multiple is undemanding for a large pharma, suggesting the stock is priced for a recovery, but the wide gap also reflects skepticism about the sustainability of current earnings. Compared to the industry average PE of 15x (based on sector data), Pfizer trades at a 22% premium on trailing earnings, but on forward earnings, it trades at a 41% discount, highlighting the market's uncertainty about near-term earnings power.
PE
18.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Pfizer's debt-to-equity ratio of 0.78 is manageable, but the company's high payout ratio of 125.8% indicates that the dividend is not fully covered by earnings, which could force a cut if cash flows deteriorate. The TTM free cash flow of $9.48 billion provides some cushion, but the company's reliance on cost-cutting to boost EPS (forward P/E of 8.8x implies a doubling of earnings) is risky if revenue growth stalls. Additionally, the Q4 2025 net loss of -$1.65 billion highlights the potential for further one-time charges, which could erode shareholder value and undermine confidence in the earnings trajectory.
FAQ
The key risks are: 1) Patent expirations on major drugs like Eliquis and Prevnar, which could erode revenue and market share, especially with competitors like Merck expanding their vaccine labels. 2) The failed GLP-1 trial, which removes a major growth catalyst and leaves Pfizer behind in the obesity drug market. 3) A high payout ratio of 125.8%, which could force a dividend cut if cash flows deteriorate. 4) Leadership instability, including the CFO departure, which could hinder execution of the 2026 targets. These risks are ranked by severity, with patent expirations being the most significant threat to long-term earnings.
The 12-month forecast is mixed, with a base case probability of 50% for a price range of $26-$29, aligning with the analyst average target of $28.75. The bull case (25% probability) targets $30-$35.46, driven by successful pipeline execution, while the bear case (25% probability) targets $23-$25, near the 52-week low, if patent erosion accelerates. The most likely scenario is a gradual recovery, with the stock trading around $28, but the wide range reflects high uncertainty. Investors should monitor quarterly earnings and pipeline updates for signs of which scenario is unfolding.
Pfizer is undervalued on forward earnings, with a P/E of 8.8x versus the industry average of 15x, implying a 41% discount. However, on trailing earnings, the P/E of 18.3x is a 22% premium to the industry, reflecting the market's skepticism about the sustainability of current earnings. The wide gap between trailing and forward multiples suggests the market expects a significant earnings recovery, which is not guaranteed. Overall, the stock is priced for a turnaround, and if the company meets its EPS estimate of $2.35, the valuation is attractive.
Pfizer is a good buy for investors seeking income and value, given its 6.9% dividend yield and forward P/E of 8.8x, which is a 41% discount to the industry average. The analyst consensus is a Buy with a 15% upside to the average target of $28.75, but the stock carries significant risks from patent expirations and a failed GLP-1 trial. For patient investors who can tolerate volatility and a potential dividend cut, the risk/reward is favorable, but it is not suitable for those seeking growth or short-term gains.
Pfizer is better suited for long-term investment, given its high dividend yield and undervalued forward P/E, which require time to play out. The stock's beta of 0.31 indicates low volatility relative to the market, but the negative relative strength suggests short-term momentum is unfavorable. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out the patent cliff and allow the pipeline to mature. Short-term traders may find opportunities in the wide price swings, but the lack of catalysts makes it less attractive for quick gains.